Short-term, high-dose testosterone treatment fails to reduce adult height in boys with constitutional tall stature
Height predictions based on three different methods (Bayley-Pinneau [BP], Tanner-Whitehouse Mark II [TW II], Roche-Wainer-Thissen [RWT]) were compared to adult heights in 19 males with constitutional tall stature previously treated with high-dose testosterone oenanthate for 6 months (group A) and 25...
Gespeichert in:
Veröffentlicht in: | European journal of pediatrics 1997-12, Vol.156 (12), p.911-915 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 915 |
---|---|
container_issue | 12 |
container_start_page | 911 |
container_title | European journal of pediatrics |
container_volume | 156 |
creator | BETTENDORF, M HEINRICH, U. E SCHÖNBERG, D. K GRULICH-HENN, J |
description | Height predictions based on three different methods (Bayley-Pinneau [BP], Tanner-Whitehouse Mark II [TW II], Roche-Wainer-Thissen [RWT]) were compared to adult heights in 19 males with constitutional tall stature previously treated with high-dose testosterone oenanthate for 6 months (group A) and 25 untreated tall males (group B). Their chronological ages (CA) at the initial evaluation of tall stature ranged from 12.1 to 16.6 years in group A and from 10.4 to 15.7 years in group B; at the time of assessment of adult height ages ranged from 18.0 to 26.5 years and from 18.4 to 25.1 years, respectively. Height measurements and predicted adult heights were expressed as height standard deviation scores (height SDS) for chronological age using the tables of Reinken and van Oost [14]. Height SDS in group A were 2.8 (range = 1.8-5.4) before testosterone treatment, 3.0 (range = 2.0-4.8) thereafter and finally 3.0 (range = 2.1-4.2) (P = NS) and in group B 2.7 (range = 0.5-4.3) and 2.4 (range = 1.3-3.5) (P = NS). A significant difference between adult height SDS and predicted height SDS according to BP was detected both in group A (3.0; range = 2.1-4.2 vs 3.6; range = 2.4-5.0. P < or = 0.004) and group B (2.4; range = 1.3-3.5 vs 3.0; range = 2.0-4.9; P < or = 0.0002), whereas no significant difference between adult height SDS and predicted height SDS according to TW II and RWT was found in either group. These data indicate that BP height predictions overestimated adult height in our patient group of treated and untreated males with constitutional tall stature. In contrast, the TW II and RWT methods were more accurate in predicting adult height in these patients, but also failed to demonstrate that testosterone therapy in boys with constitutional tall stature can be limited to a 6-month period in order to reduce adult height.
The widely used height prediction method of BP is inaccurate in boys with constitutional tall stature. High dose testosterone treatment fails to reduce adult height in these individuals when discontinued before complete closure of the epiphyses. |
doi_str_mv | 10.1007/s004310050741 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79536587</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79536587</sourcerecordid><originalsourceid>FETCH-LOGICAL-c344t-f53e8a77edbd6257a04b6bd24daf6249d4d5f5ff13ce839e1c65e395aba781313</originalsourceid><addsrcrecordid>eNpdkUtrFjEUhoNY6tfq0qUQpLhyNJncZpZSai0UXKjrIZOcOCmZSc3JIP33RvpR0NW5PeflXAh5zdkHzpj5iIxJ0TzFjOTPyIFL0XecGf2cHJiQrNN8HF-QM8Q71viRD6fkdJRKCMMPpHxbcqldhbK-p0v8uXQ-I9AKWDO2bN5aUMDWFbZKg40Jac20gN8dUOv3VOkCra_SuNE5PyD9HetCXd6wxrrXmDebaLUpUay27gVekpNgE8Kroz0nPz5ffb_80t1-vb65_HTbOSFl7YISMFhjwM9e98pYJmc9-156G3QvRy-9CioELhwMYgTutAIxKjtbM3DBxTl596h7X_KvvS00rREdpGQ3yDtOZlRCq8E08O1_4F3eSxsbp77no2RasgZ1j5ArGbFAmO5LXG15mDib_j5i-ucRjX9zFN3nFfwTfbx8q18c6xadTaHYzUV8wnqmmRFK_AF8o5FN</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>221940640</pqid></control><display><type>article</type><title>Short-term, high-dose testosterone treatment fails to reduce adult height in boys with constitutional tall stature</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>BETTENDORF, M ; HEINRICH, U. E ; SCHÖNBERG, D. K ; GRULICH-HENN, J</creator><creatorcontrib>BETTENDORF, M ; HEINRICH, U. E ; SCHÖNBERG, D. K ; GRULICH-HENN, J</creatorcontrib><description>Height predictions based on three different methods (Bayley-Pinneau [BP], Tanner-Whitehouse Mark II [TW II], Roche-Wainer-Thissen [RWT]) were compared to adult heights in 19 males with constitutional tall stature previously treated with high-dose testosterone oenanthate for 6 months (group A) and 25 untreated tall males (group B). Their chronological ages (CA) at the initial evaluation of tall stature ranged from 12.1 to 16.6 years in group A and from 10.4 to 15.7 years in group B; at the time of assessment of adult height ages ranged from 18.0 to 26.5 years and from 18.4 to 25.1 years, respectively. Height measurements and predicted adult heights were expressed as height standard deviation scores (height SDS) for chronological age using the tables of Reinken and van Oost [14]. Height SDS in group A were 2.8 (range = 1.8-5.4) before testosterone treatment, 3.0 (range = 2.0-4.8) thereafter and finally 3.0 (range = 2.1-4.2) (P = NS) and in group B 2.7 (range = 0.5-4.3) and 2.4 (range = 1.3-3.5) (P = NS). A significant difference between adult height SDS and predicted height SDS according to BP was detected both in group A (3.0; range = 2.1-4.2 vs 3.6; range = 2.4-5.0. P < or = 0.004) and group B (2.4; range = 1.3-3.5 vs 3.0; range = 2.0-4.9; P < or = 0.0002), whereas no significant difference between adult height SDS and predicted height SDS according to TW II and RWT was found in either group. These data indicate that BP height predictions overestimated adult height in our patient group of treated and untreated males with constitutional tall stature. In contrast, the TW II and RWT methods were more accurate in predicting adult height in these patients, but also failed to demonstrate that testosterone therapy in boys with constitutional tall stature can be limited to a 6-month period in order to reduce adult height.
The widely used height prediction method of BP is inaccurate in boys with constitutional tall stature. High dose testosterone treatment fails to reduce adult height in these individuals when discontinued before complete closure of the epiphyses.</description><identifier>ISSN: 0340-6199</identifier><identifier>EISSN: 1432-1076</identifier><identifier>DOI: 10.1007/s004310050741</identifier><identifier>PMID: 9453371</identifier><identifier>CODEN: EJPEDT</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>Adolescent ; Adult ; Biological and medical sciences ; Body Constitution ; Body Height ; Child ; Endocrinology ; Growth Disorders - drug therapy ; Height ; Hormones. Endocrine system ; Humans ; Male ; Males ; Medical sciences ; Pediatrics ; Pharmacology. Drug treatments ; Retrospective Studies ; Testosterone ; Testosterone - therapeutic use ; Treatment Failure</subject><ispartof>European journal of pediatrics, 1997-12, Vol.156 (12), p.911-915</ispartof><rights>1998 INIST-CNRS</rights><rights>Springer-Verlag Berlin Heidelberg 1997</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c344t-f53e8a77edbd6257a04b6bd24daf6249d4d5f5ff13ce839e1c65e395aba781313</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2060735$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9453371$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BETTENDORF, M</creatorcontrib><creatorcontrib>HEINRICH, U. E</creatorcontrib><creatorcontrib>SCHÖNBERG, D. K</creatorcontrib><creatorcontrib>GRULICH-HENN, J</creatorcontrib><title>Short-term, high-dose testosterone treatment fails to reduce adult height in boys with constitutional tall stature</title><title>European journal of pediatrics</title><addtitle>Eur J Pediatr</addtitle><description>Height predictions based on three different methods (Bayley-Pinneau [BP], Tanner-Whitehouse Mark II [TW II], Roche-Wainer-Thissen [RWT]) were compared to adult heights in 19 males with constitutional tall stature previously treated with high-dose testosterone oenanthate for 6 months (group A) and 25 untreated tall males (group B). Their chronological ages (CA) at the initial evaluation of tall stature ranged from 12.1 to 16.6 years in group A and from 10.4 to 15.7 years in group B; at the time of assessment of adult height ages ranged from 18.0 to 26.5 years and from 18.4 to 25.1 years, respectively. Height measurements and predicted adult heights were expressed as height standard deviation scores (height SDS) for chronological age using the tables of Reinken and van Oost [14]. Height SDS in group A were 2.8 (range = 1.8-5.4) before testosterone treatment, 3.0 (range = 2.0-4.8) thereafter and finally 3.0 (range = 2.1-4.2) (P = NS) and in group B 2.7 (range = 0.5-4.3) and 2.4 (range = 1.3-3.5) (P = NS). A significant difference between adult height SDS and predicted height SDS according to BP was detected both in group A (3.0; range = 2.1-4.2 vs 3.6; range = 2.4-5.0. P < or = 0.004) and group B (2.4; range = 1.3-3.5 vs 3.0; range = 2.0-4.9; P < or = 0.0002), whereas no significant difference between adult height SDS and predicted height SDS according to TW II and RWT was found in either group. These data indicate that BP height predictions overestimated adult height in our patient group of treated and untreated males with constitutional tall stature. In contrast, the TW II and RWT methods were more accurate in predicting adult height in these patients, but also failed to demonstrate that testosterone therapy in boys with constitutional tall stature can be limited to a 6-month period in order to reduce adult height.
The widely used height prediction method of BP is inaccurate in boys with constitutional tall stature. High dose testosterone treatment fails to reduce adult height in these individuals when discontinued before complete closure of the epiphyses.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Body Constitution</subject><subject>Body Height</subject><subject>Child</subject><subject>Endocrinology</subject><subject>Growth Disorders - drug therapy</subject><subject>Height</subject><subject>Hormones. Endocrine system</subject><subject>Humans</subject><subject>Male</subject><subject>Males</subject><subject>Medical sciences</subject><subject>Pediatrics</subject><subject>Pharmacology. Drug treatments</subject><subject>Retrospective Studies</subject><subject>Testosterone</subject><subject>Testosterone - therapeutic use</subject><subject>Treatment Failure</subject><issn>0340-6199</issn><issn>1432-1076</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkUtrFjEUhoNY6tfq0qUQpLhyNJncZpZSai0UXKjrIZOcOCmZSc3JIP33RvpR0NW5PeflXAh5zdkHzpj5iIxJ0TzFjOTPyIFL0XecGf2cHJiQrNN8HF-QM8Q71viRD6fkdJRKCMMPpHxbcqldhbK-p0v8uXQ-I9AKWDO2bN5aUMDWFbZKg40Jac20gN8dUOv3VOkCra_SuNE5PyD9HetCXd6wxrrXmDebaLUpUay27gVekpNgE8Kroz0nPz5ffb_80t1-vb65_HTbOSFl7YISMFhjwM9e98pYJmc9-156G3QvRy-9CioELhwMYgTutAIxKjtbM3DBxTl596h7X_KvvS00rREdpGQ3yDtOZlRCq8E08O1_4F3eSxsbp77no2RasgZ1j5ArGbFAmO5LXG15mDib_j5i-ucRjX9zFN3nFfwTfbx8q18c6xadTaHYzUV8wnqmmRFK_AF8o5FN</recordid><startdate>19971201</startdate><enddate>19971201</enddate><creator>BETTENDORF, M</creator><creator>HEINRICH, U. E</creator><creator>SCHÖNBERG, D. K</creator><creator>GRULICH-HENN, J</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>19971201</creationdate><title>Short-term, high-dose testosterone treatment fails to reduce adult height in boys with constitutional tall stature</title><author>BETTENDORF, M ; HEINRICH, U. E ; SCHÖNBERG, D. K ; GRULICH-HENN, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c344t-f53e8a77edbd6257a04b6bd24daf6249d4d5f5ff13ce839e1c65e395aba781313</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Body Constitution</topic><topic>Body Height</topic><topic>Child</topic><topic>Endocrinology</topic><topic>Growth Disorders - drug therapy</topic><topic>Height</topic><topic>Hormones. Endocrine system</topic><topic>Humans</topic><topic>Male</topic><topic>Males</topic><topic>Medical sciences</topic><topic>Pediatrics</topic><topic>Pharmacology. Drug treatments</topic><topic>Retrospective Studies</topic><topic>Testosterone</topic><topic>Testosterone - therapeutic use</topic><topic>Treatment Failure</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BETTENDORF, M</creatorcontrib><creatorcontrib>HEINRICH, U. E</creatorcontrib><creatorcontrib>SCHÖNBERG, D. K</creatorcontrib><creatorcontrib>GRULICH-HENN, J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pediatrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BETTENDORF, M</au><au>HEINRICH, U. E</au><au>SCHÖNBERG, D. K</au><au>GRULICH-HENN, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Short-term, high-dose testosterone treatment fails to reduce adult height in boys with constitutional tall stature</atitle><jtitle>European journal of pediatrics</jtitle><addtitle>Eur J Pediatr</addtitle><date>1997-12-01</date><risdate>1997</risdate><volume>156</volume><issue>12</issue><spage>911</spage><epage>915</epage><pages>911-915</pages><issn>0340-6199</issn><eissn>1432-1076</eissn><coden>EJPEDT</coden><abstract>Height predictions based on three different methods (Bayley-Pinneau [BP], Tanner-Whitehouse Mark II [TW II], Roche-Wainer-Thissen [RWT]) were compared to adult heights in 19 males with constitutional tall stature previously treated with high-dose testosterone oenanthate for 6 months (group A) and 25 untreated tall males (group B). Their chronological ages (CA) at the initial evaluation of tall stature ranged from 12.1 to 16.6 years in group A and from 10.4 to 15.7 years in group B; at the time of assessment of adult height ages ranged from 18.0 to 26.5 years and from 18.4 to 25.1 years, respectively. Height measurements and predicted adult heights were expressed as height standard deviation scores (height SDS) for chronological age using the tables of Reinken and van Oost [14]. Height SDS in group A were 2.8 (range = 1.8-5.4) before testosterone treatment, 3.0 (range = 2.0-4.8) thereafter and finally 3.0 (range = 2.1-4.2) (P = NS) and in group B 2.7 (range = 0.5-4.3) and 2.4 (range = 1.3-3.5) (P = NS). A significant difference between adult height SDS and predicted height SDS according to BP was detected both in group A (3.0; range = 2.1-4.2 vs 3.6; range = 2.4-5.0. P < or = 0.004) and group B (2.4; range = 1.3-3.5 vs 3.0; range = 2.0-4.9; P < or = 0.0002), whereas no significant difference between adult height SDS and predicted height SDS according to TW II and RWT was found in either group. These data indicate that BP height predictions overestimated adult height in our patient group of treated and untreated males with constitutional tall stature. In contrast, the TW II and RWT methods were more accurate in predicting adult height in these patients, but also failed to demonstrate that testosterone therapy in boys with constitutional tall stature can be limited to a 6-month period in order to reduce adult height.
The widely used height prediction method of BP is inaccurate in boys with constitutional tall stature. High dose testosterone treatment fails to reduce adult height in these individuals when discontinued before complete closure of the epiphyses.</abstract><cop>Heidelberg</cop><cop>Berlin</cop><pub>Springer</pub><pmid>9453371</pmid><doi>10.1007/s004310050741</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0340-6199 |
ispartof | European journal of pediatrics, 1997-12, Vol.156 (12), p.911-915 |
issn | 0340-6199 1432-1076 |
language | eng |
recordid | cdi_proquest_miscellaneous_79536587 |
source | MEDLINE; SpringerNature Journals |
subjects | Adolescent Adult Biological and medical sciences Body Constitution Body Height Child Endocrinology Growth Disorders - drug therapy Height Hormones. Endocrine system Humans Male Males Medical sciences Pediatrics Pharmacology. Drug treatments Retrospective Studies Testosterone Testosterone - therapeutic use Treatment Failure |
title | Short-term, high-dose testosterone treatment fails to reduce adult height in boys with constitutional tall stature |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T17%3A29%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Short-term,%20high-dose%20testosterone%20treatment%20fails%20to%20reduce%20adult%20height%20in%20boys%20with%20constitutional%20tall%20stature&rft.jtitle=European%20journal%20of%20pediatrics&rft.au=BETTENDORF,%20M&rft.date=1997-12-01&rft.volume=156&rft.issue=12&rft.spage=911&rft.epage=915&rft.pages=911-915&rft.issn=0340-6199&rft.eissn=1432-1076&rft.coden=EJPEDT&rft_id=info:doi/10.1007/s004310050741&rft_dat=%3Cproquest_cross%3E79536587%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=221940640&rft_id=info:pmid/9453371&rfr_iscdi=true |